High concentrations of lipopolysaccharide-binding protein in serum of patients with severe sepsis or septic shock inhibit the lipopolysaccharide response in human monocytes.

Lipopolysaccharide-binding protein (LBP), an acute-phase protein recognizing lipopolysaccharide (LPS), catalyzes in low concentrations its transfer to the cellular LPS receptor consisting of CD14 and Toll-like receptor-4. It has recently been shown that high concentrations of recombinant LBP can protect mice in a peritonitis model from the lethal effects of LPS. To determine whether in humans the acute-phase rise of LBP concentrations can inhibit LPS binding to monocytes and induction of proinflammatory cytokines, LBP concentrations were analyzed in 63 patients meeting the American College of Chest Physicians/Society of Critical Care Medicine criteria of severe sepsis or septic shock and the ability of these sera to modulate LPS effects in vitro was assessed employing different assays. Transfer of fluorescein isothiocyanate-labeled LPS to human monocytes was assessed by a fluorescence-activated cell sorter-based method, and activation of monocytes was investigated by measuring LPS-induced tumor necrosis factor-alpha secretion in the presence of the sera. Anti-LBP antibodies and recombinant human LBP were instrumental for depletion and reconstitution of acute-phase sera and subsequent assessment of their modulating effects on LPS activity. Sera of patients with severe sepsis/septic shock exhibited a diminished LPS transfer activity and LPS-induced tumor necrosis factor-alpha secretion as compared with sera from healthy controls. LBP depletion of sepsis sera and addition of rhLBP resulting in concentrations found in severe sepsis confirmed that LBP was the major serum component responsible for the observed effects. In summary, the inhibition of LPS effects by high concentrations of LBP in acute-phase serum, as described here, may represent a novel defense mechanism of the host in severe sepsis and during bacterial infections.

[1]  K. Triantafilou,et al.  A CD14-independent LPS receptor cluster , 2001, Nature Immunology.

[2]  J. Silver,et al.  Induction of a Novel Mechanism of Accelerated Bacterial Clearance by Lipopolysaccharide in CD14-Deficient and Toll-Like Receptor 4-Deficient Mice1 , 2001, The Journal of Immunology.

[3]  W. Buurman,et al.  LPS-binding protein circulates in association with apoB-containing lipoproteins and enhances endotoxin-LDL/VLDL interaction. , 2001, The Journal of clinical investigation.

[4]  T. Calandra,et al.  Role of Plasma, Lipopolysaccharide-Binding Protein, and CD14 in Response of Mouse Peritoneal Exudate Macrophages to Endotoxin , 2001, Infection and Immunity.

[5]  B. Jaber,et al.  Interleukin-1 receptor antagonist synthesis by peripheral blood mononuclear cells: a novel predictor of morbidity among hemodialysis patients. , 2000, Journal of the American Society of Nephrology : JASN.

[6]  K. Moore,et al.  Divergent Response to LPS and Bacteria in CD14-Deficient Murine Macrophages1 , 2000, The Journal of Immunology.

[7]  M. Poppelier,et al.  Serum Amyloid P Component Prevents High-Density Lipoprotein-Mediated Neutralization of Lipopolysaccharide , 2000, Infection and Immunity.

[8]  Charles J. Fisher,et al.  Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: Time for a reevaluation , 2000, Critical care medicine.

[9]  H. Flad,et al.  Binding of lipopolysaccharide (LPS) to CHO cells does not correlate with LPS‐induced NF‐κB activation , 2000, European journal of immunology.

[10]  C. Brun-Buisson,et al.  The epidemiology of the systemic inflammatory response , 2000, Intensive Care Medicine.

[11]  H. Volk,et al.  Impaired antigen presentation by human monocytes during endotoxin tolerance. , 2000, Blood.

[12]  E. Wouters,et al.  Production of the acute-phase protein lipopolysaccharide-binding protein by respiratory type II epithelial cells: implications for local defense to bacterial endotoxins. , 2000, American journal of respiratory cell and molecular biology.

[13]  S. Opal,et al.  Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. , 1999, The Journal of infectious diseases.

[14]  W. Buurman,et al.  Lipopolysaccharide binding protein and serum amyloid A secretion by human intestinal epithelial cells during the acute phase response. , 1999, Journal of immunology.

[15]  K. Reinhart,et al.  Treating patients with severe sepsis. , 1999, The New England journal of medicine.

[16]  R. Landmann,et al.  Monoclonal antibodies to murine lipopolysaccharide (LPS)-binding protein (LBP) protect mice from lethal endotoxemia by blocking either the binding of LPS to LBP or the presentation of LPS/LBP complexes to CD14. , 1999, Journal of immunology.

[17]  I. Kushner,et al.  Acute-phase proteins and other systemic responses to inflammation. , 1999, The New England journal of medicine.

[18]  R. Ulevitch,et al.  Recognition of gram-negative bacteria and endotoxin by the innate immune system. , 1999, Current opinion in immunology.

[19]  P. Ricciardi-Castagnoli,et al.  Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. , 1998, Science.

[20]  C. Natanson,et al.  The sirens' songs of confirmatory sepsis trials: selection bias and sampling error. , 1998, Critical Care Medicine.

[21]  R. Schumann,et al.  LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria. , 1998, The Journal of clinical investigation.

[22]  J. Cavaillon,et al.  Reduced ex vivo interleukin-8 production by neutrophils in septic and nonseptic systemic inflammatory response syndrome. , 1998, Blood.

[23]  M. Wurfel,et al.  Targeted Deletion of the Lipopolysaccharide (LPS)-binding Protein Gene Leads to Profound Suppression of LPS Responses Ex Vivo, whereas In Vivo Responses Remain Intact , 1997, The Journal of experimental medicine.

[24]  G. Rune,et al.  Lipopolysaccharide-binding protein is required to combat a murine Gram-negative bacterial infection , 1997, Nature.

[25]  K. Asadullah,et al.  Monocyte deactivation in septic patients: Restoration by IFN-γ treatment , 1997, Nature Medicine.

[26]  M. Wurfel,et al.  Lipopolysaccharide-binding protein and soluble CD14 transfer lipopolysaccharide to phospholipid bilayers: preferential interaction with particular classes of lipid. , 1997, Journal of immunology.

[27]  J. E. Doran,et al.  Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia , 1996, The Journal of experimental medicine.

[28]  F. Herrmann,et al.  The lipopolysaccharide-binding protein is a secretory class 1 acute-phase protein whose gene is transcriptionally activated by APRF/STAT/3 and other cytokine-inducible nuclear proteins , 1996, Molecular and cellular biology.

[29]  S. Wright,et al.  Neutralization and Transfer of Lipopolysaccharide by Phospholipid Transfer Protein (*) , 1996, The Journal of Biological Chemistry.

[30]  P. Barie,et al.  Low lipid concentrations in critical illness: implications for preventing and treating endotoxemia. , 1996, Critical care medicine.

[31]  R R Schumann,et al.  Bacterial endotoxin: Chemical constitution, biological recognition, host response, and immunological detoxification. , 1996, Current topics in microbiology and immunology.

[32]  S. Pillai,et al.  Innate immunity. , 1996, Current opinion in immunology.

[33]  François Gouin,et al.  Incidence, Risk Factors, and Outcome of Severe Sepsis and Septic Shock in Adults: A Multicenter Prospective Study in Intensive Care Units , 1995 .

[34]  F Doyon,et al.  Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. , 1995, JAMA.

[35]  G. Ramsay,et al.  Lipopolysaccharide toxicity-regulating proteins in bacteremia. , 1995, The Journal of infectious diseases.

[36]  M. Wurfel,et al.  Soluble CD14 acts as a shuttle in the neutralization of lipopolysaccharide (LPS) by LPS-binding protein and reconstituted high density lipoprotein , 1995, The Journal of experimental medicine.

[37]  J. Gegner,et al.  Lipopolysaccharide (LPS) Signal Transduction and Clearance , 1995, The Journal of Biological Chemistry.

[38]  F. Schildberg,et al.  Downregulation of proinflammatory cytokine release in whole blood from septic patients. , 1995, Blood.

[39]  T. Calandra,et al.  Lipopolysaccharide (LPS)-binding protein in human serum determines the tumor necrosis factor response of monocytes to LPS. , 1994, The Journal of infectious diseases.

[40]  M. Wurfel,et al.  Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS , 1994, The Journal of experimental medicine.

[41]  M. Glauser,et al.  Mode of action of anti-lipopolysaccharide-binding protein antibodies for prevention of endotoxemic shock in mice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[42]  J. Silver,et al.  Recombinant soluble CD14 inhibits LPS-induced tumor necrosis factor-alpha production by cells in whole blood. , 1994, Journal of immunology.

[43]  P. Barie,et al.  Changes in polymorphonuclear leukocyte surface and plasma bactericidal/permeability-increasing protein and plasma lipopolysaccharide binding protein during endotoxemia or sepsis. , 1994, Archives of surgery.

[44]  A. Walsh,et al.  In vivo protection against endotoxin by plasma high density lipoprotein. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[45]  W. Buurman,et al.  Antagonistic effects of lipopolysaccharide binding protein and bactericidal/permeability-increasing protein on lipopolysaccharide-induced cytokine release by mononuclear phagocytes. Competition for binding to lipopolysaccharide. , 1993, Journal of immunology.

[46]  M. Glauser,et al.  Competition between bactericidal/permeability-increasing protein and lipopolysaccharide-binding protein for lipopolysaccharide binding to monocytes. , 1993, The Journal of infectious diseases.

[47]  R. Ulevitch,et al.  Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[48]  I. L. Cohen.  Guidelines for the use of innovative therapies in sepsis. , 1993, Critical care medicine.

[49]  B. Finlay,et al.  Soluble CD14 participates in the response of cells to lipopolysaccharide , 1992, The Journal of experimental medicine.

[50]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. , 1992, Chest.

[51]  W. Knaus,et al.  The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. , 1991, Chest.

[52]  J. Cavaillon,et al.  Dysregulation of in vitro cytokine production by monocytes during sepsis. , 1991, The Journal of clinical investigation.

[53]  H. Beger,et al.  Correlation between endotoxin‐neutralizing capacity of human plasma as tested by the limulus‐amebocyte‐lysate‐test and plasma protein levels , 1990, FEBS letters.

[54]  R. Ulevitch,et al.  Structure and function of lipopolysaccharide binding protein. , 1990, Science.

[55]  R. Ulevitch,et al.  CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. , 1990, Science.

[56]  B. Yangco,et al.  CDC definitions for nosocomial infections. , 1989, American journal of infection control.

[57]  J M Hughes,et al.  CDC definitions for nosocomial infections, 1988. , 1988, American journal of infection control.

[58]  C. Nathan,et al.  Secretory products of macrophages. , 1987, The Journal of clinical investigation.